MYCOPHENOLATE-MOFETIL - EFFECTS ON CLINICAL TRANSPLANTATION

Mycophenolate mofetil (MMF) is the morpholinoethylester prodrug of myc ophenolic acid, an agent which inhibits the proliferation of B and T l ymphocytes through the noncompetitive, reversible inhibition of inosin e monophosphate dehydrogenase, itself a key enzyme in the de novo synt hetic pathway of guanosine nucleotides. Currently, MMF is approved for the prevention of acute renal allograft rejection when used in combin ation with cyclosporin and corticosteroids. Several studies have also demonstrated that this drug is useful in the treatment of refractory r ejection in renal, heart and liver transplant recipients.